Laure Elens

List of Publications by Year
in descending order

74 papers	3,419 citations	159585 30 h-index	149698 56 g-index
74 all docs	74 docs citations	74 times ranked	3274 citing authors

#	Article	IF	Citations
1	Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report. Therapeutic Drug Monitoring, 2019, 41, 261-307.	2.0	374
2	A New Functional CYP3A4 Intron 6 Polymorphism Significantly Affects Tacrolimus Pharmacokinetics in Kidney Transplant Recipients. Clinical Chemistry, 2011, 57, 1574-1583.	3.2	211
3	The Role of Pharmacogenetics in the Disposition of and Response to Tacrolimus in Solid Organ Transplantation. Clinical Pharmacokinetics, 2014, 53, 123-139.	3.5	186
4	CYP3A4*22: promising newly identifiedCYP3A4variant allele for personalizing pharmacotherapy. Pharmacogenomics, 2013, 14, 47-62.	1.3	178
5	CYP3A5 and ABCB1 Polymorphisms and Tacrolimus Pharmacokinetics in Renal Transplant Candidates: Guidelines from an Experimental Study. American Journal of Transplantation, 2006, 6, 2706-2713.	4.7	160
6	Effect of a new functional CYP3A4 polymorphism on calcineurin inhibitorsâ€™ dose requirements and trough blood levels in stable renal transplant patients. Pharmacogenomics, 2011, 12, 1383-1396.	1.3	139
7	CYP3A5 and ABCB1 polymorphisms influence tacrolimus concentrations in peripheral blood mononuclear cells after renal transplantation. Pharmacogenomics, 2010, 11, 703-714.	1.3	97
8	Novel CYP3A4 intron 6 single nucleotide polymorphism is associated with simvastatin-mediated cholesterol reduction in The Rotterdam Study. Pharmacogenetics and Genomics, 2011, 21, 861-866.	1.5	97
9	1199G>A and 2677G>T/A polymorphisms of ABCB1 independently affect tacrolimus concentration in hepatic tissue after liver transplantation. Pharmacogenetics and Genomics, 2007, 17, 873-883.	1.5	94
10	Personalized Therapy for Mycophenolate: Consensus Report by the International Association of Therapeutic Drug Monitoring and Clinical Toxicology. Therapeutic Drug Monitoring, 2021, 43, 150-200.	2.0	89
11	CYP3A4*22 Genotype and Systemic Exposure Affect Paclitaxel-Induced Neurotoxicity. Clinical Cancer Research, 2013, 19, 3316-3324.	7.0	88
12	Impact of POR*28 on the Pharmacokinetics of Tacrolimus and Cyclosporine A in Renal Transplant Patients. Therapeutic Drug Monitoring, 2014, 36, 71-79.	2.0	81
13	Influence of Polymorphic OATP1B-Type Carriers on the Disposition of Docetaxel. Clinical Cancer Research, 2012, 18, 4433-4440.	7.0	80
14	The new CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) is associated with an increased risk of delayed graft function and worse renal function in cyclosporine-treated kidney transplant patients. Pharmacogenetics and Genomics, 2012, 22, 373-380.	1.5	73
15	Impact of CYP3A4*22 Allele on Tacrolimus Pharmacokinetics in Early Period After Renal Transplantation. Therapeutic Drug Monitoring, 2013, 35, 608-616.	2.0	71
16	A New CYP3A5*3 and CYP3A4*22 Cluster Influencing Tacrolimus Target Concentrations: A Population Approach. Clinical Pharmacokinetics, 2017, 56, 963-975.	3.5	69
17	Rivaroxaban plasma levels in patients admitted for bleeding events: insights from a prospective study. Thrombosis Journal, 2018, 16, 28.	2.1	63
18	A population pharmacokinetic model to predict the individual starting dose of tacrolimus in adult renal transplant recipients. British Journal of Clinical Pharmacology, 2019, 85, 601-615.	2.4	56

#	Article	IF	Citations
19	Influence of host genetic factors on efavirenz plasma and intracellular pharmacokinetics in HIV-1-infected patients. Pharmacogenomics, 2010, 11, 1223-1234.	1.3	53
20	The combination of CYP3A4*22 and CYP3A5*3 single-nucleotide polymorphisms determines tacrolimus dose requirement after kidney transplantation. Pharmacogenetics and Genomics, 2017, 27, 313-322.	1.5	52
21	CYP3A4 intron 6 C>T SNP (CYP3A4*22) encodes lower CYP3A4 activity in cancer patients, as measured with probes midazolam and erythromycin. Pharmacogenomics, 2013, 14, 137-149.	1.3	51
22	CYP3A4*22 and CYP3A combined genotypes both correlate with tacrolimus disposition in pediatric heart transplant recipients. Pharmacogenomics, 2013, 14, 1027-1036.	1.3	49
23	Pharmacologic Treatment of Transplant Recipients Infected With SARS-CoV-2: Considerations Regarding Therapeutic Drug Monitoring and Drugâ€“Drug Interactions. Therapeutic Drug Monitoring, 2020, 42, 360-368.	2.0	48
24	The CYP3A4*22 C>T single nucleotide polymorphism is associated with reduced midazolam and tacrolimus clearance in stable renal allograft recipients. Pharmacogenomics Journal, 2015, 15, 144-152.	2.0	46
25	Dental Apical Papilla as Therapy for Spinal Cord Injury. Journal of Dental Research, 2015, 94, 1575-1581.	5.2	45
26	Tacrolimus Updated Guidelines through popPK Modeling: How to Benefit More from CYP3A Pre-emptive Genotyping Prior to Kidney Transplantation. Frontiers in Pharmacology, 2017, 8, 358.	3.5	44
27	Clinical implementation of pharmacogenetics in kidney transplantation: calcineurin inhibitors in the starting blocks. British Journal of Clinical Pharmacology, 2014, 77, 715-728.	2.4	40
28	ABCB1 1199G>A Genetic Polymorphism (Rs2229109) Influences the Intracellular Accumulation of Tacrolimus in HEK293 and K562 Recombinant Cell Lines. PLoS ONE, 2014, 9, e91555.	2.5	38
29	The <scp>CYP</scp>3A4*22 allele affects the predictive value of a pharmacogenetic algorithm predicting tacrolimus predose concentrations. British Journal of Clinical Pharmacology, 2013, 75, 1545-1547.	2.4	35
30	Impact of POR*28 on the clinical pharmacokinetics of CYP3A phenotyping probes midazolam and erythromycin. Pharmacogenetics and Genomics, 2013, 23, 148-155.	1.5	35
31	CYP3A4â^—22 Genotyping in Clinical Practice: Ready for Implementation?. Frontiers in Genetics, 2021, 12, 711943.	2.3	32
32	Validation and clinical application of a high performance liquid chromatography tandem mass spectrometry (LC-MS/MS) method for the quantitative determination of 10 anti-retrovirals in human peripheral blood mononuclear cells. Journal of Chromatography B: Analytical Technologies in the Biomedical and Life Sciences, 2009, 877, 1805-1814.	2.3	31
33	Impact of ABCB1 1236Câ€‰>â€‰T-2677Gâ€‰>â€‰T-3435Câ€‰>â€‰T polymorphisms on the anti-proliferative activity of imatinib, nilotinib, dasatinib and ponatinib. Scientific Reports, 2016, 6, 29559.	3.3	31
34	Single-nucleotide polymorphisms in P450 oxidoreductase and peroxisome proliferator-activated receptor-Î± are associated with the development of new-onset diabetes after transplantation in kidney transplant recipients treated with tacrolimus. Pharmacogenetics and Genomics, 2013, 23, 649-657.	1.5	30
35	CYP2C9*2 Allele Increases Risk for Hypoglycemia in POR*1/*1 Type 2 Diabetic Patients Treated with Sulfonylureas. Experimental and Clinical Endocrinology and Diabetes, 2014, 122, 60-63.	1.2	30
36	Functional defect caused by the 4544G>A SNP in ABCC2. Pharmacogenetics and Genomics, 2011, 21, 884-893.	1.5	29

#	Article	IF	Citations
37	Influence of donorâ€“recipient CYP3A4/5 genotypes, age and fluconazole on tacrolimus pharmacokinetics in pediatric liver transplantation: a population approach. Pharmacogenomics, 2014, 15, 1207-1221.	1.3	29
38	Rescue morphine in mechanically ventilated newborns associated with combined OPRM1 and COMT genotype. Pharmacogenomics, 2014, 15, 1287-1295.	1.3	29
39	Association between ABCC2 polymorphism and lopinavir accumulation in peripheral blood mononuclear cells of HIV-infected patients. Pharmacogenomics, 2009, 10, 1589-1597.	1.3	28
40	Effect of UGT2B7 -900G>A (-842G>A; rs7438135) on morphine glucuronidation in preterm newborns: results from a pilot cohort. Pharmacogenomics, 2014, 15, 1589-1597.	1.3	27
41	Genetic Predisposition to Poor Opioid Response in Preterm Infants: Impact of KCNJ6 and COMT Polymorphisms on Pain Relief After Endotracheal Intubation. Therapeutic Drug Monitoring, 2016, 38, 525-533.	2.0	24
42	A Pharmacogenetic Predictive Model for Paclitaxel Clearance Based on the DMET Platform. Clinical Cancer Research, 2013, 19, 5210-5217.	7.0	23
43	ABCB1 1199G>A polymorphism (rs2229109) affects the transport of imatinib, nilotinib and dasatinib. Pharmacogenomics, 2016, 17, 883-890.	1.3	22
44	Advanced cancer pain: the search for genetic factors correlated with interindividual variability in opioid requirement. Pharmacogenomics, 2017, 18, 1133-1142.	1.3	22
45	SLC22A1/OCT1 Genotype Affects O-desmethyltramadol Exposure in Newborn Infants. Therapeutic Drug Monitoring, 2016, 38, 487-492.	2.0	20
46	Quantification of 8 HIV-Protease Inhibitors and 2 Nonnucleoside Reverse Transcriptase Inhibitors by Ultra-Performance Liquid Chromatography with Diode Array Detection. Clinical Chemistry, 2009, 55, 170-174.	3.2	19
47	Genotype-based tacrolimus dosing guidelines: with or without CYP3A4*22?. Pharmacogenomics, 2017, 18, 1473-1480.	1.3	19
48	Predictors of tacrolimus pharmacokinetic variability: current evidences and future perspectives. Expert Opinion on Drug Metabolism and Toxicology, 2020, 16, 769-782.	3.3	19
49	Pharmacogenetics in Kidney Transplantation. Molecular Diagnosis and Therapy, 2012, 16, 331-345.	3.8	18
50	Impact of UGT1A1 polymorphisms on Raltegravir and its glucuronide plasma concentrations in a cohort of HIV-1 infected patients. Scientific Reports, 2018, 8, 7359.	3.3	18
51	Donor age and ABCB1 1199G>A genetic polymorphism are independent factors affecting long-term renal function after kidney transplantation. Journal of Surgical Research, 2012, 178, 988-995.	1.6	17
52	POR*28 SNP is associated with lipid response to atorvastatin in children and adolescents with familial hypercholesterolemia. Pharmacogenomics, 2014, 15, 1963-1972.	1.3	17
53	No effect of CYP3A4 intron 6 C>T polymorphism (CYP3A4*22) on lipid-lowering response to statins in Greek patients with primary hypercholesterolemia. Drug Metabolism and Personalized Therapy, 2015, 30, 43-48.	0.6	16
54	Quantification of darunavir and etravirine in human peripheral blood mononuclear cells using high performance liquid chromatography tandem mass spectrometry (LCâ€“MS/MS), clinical application in a cohort of 110 HIV-1 infected patients and evidence of a potential drugâ€“drug interaction. Clinical Biochemistry, 2016, 49, 580-586.	1.9	16

#	Article	IF	Citations
55	Genetic variation in the PPARA gene is associated with simvastatin-mediated cholesterol reduction in the Rotterdam Study. Pharmacogenomics, 2013, 14, 1295-1304.	1.3	15
56	Mycophenolic Acid-Related Anemia and Leucopenia in Renal Transplant Recipients Are Related to Genetic Polymorphisms in CYP2C8. Transplantation, 2012, 93, e39-e40.	1.0	13
57	Effect of ABCB1 genetic polymorphisms on the transport of rivaroxaban in HEK293 recombinant cell lines. Scientific Reports, 2018, 8, 10514.	3.3	12
58	Lack of Association of the P450 Oxidoreductase *28 Single Nucleotide Polymorphism with the Lipid-Lowering Effect of Statins in Hypercholesterolemic Patients. Molecular Diagnosis and Therapy, 2014, 18, 323-31.	3.8	11
59	Interaction between Darunavir and Etravirine Is Partly Mediated by CYP3A5 Polymorphism. PLoS ONE, 2016, 11, e0165631.	2.5	11
60	Association of CYP3A variants with kidney transplant outcomes. Renal Failure, 2015, 37, 562-566.	2.1	9
61	Atorvastatin population pharmacokinetics in a realâ€life setting: Influence of genetic polymorphisms and association with clinical response. Clinical and Translational Science, 2022, 15, 667-679.	3.1	8
62	Detection of a rare CYP3A4 variant in a transplant patient characterized by a tacrolimus poor metabolizer phenotype. Pharmacogenomics, 2018, 19, 305-310.	1.3	7
63	Pharmacogenetic associations with cytochrome P450 in antiretroviral therapy: what does the future hold?. Expert Opinion on Drug Metabolism and Toxicology, 2018, 14, 601-611.	3.3	6
64	The pharmacogenetics of tacrolimus and its implications for personalized therapy in kidney transplant recipients. Expert Review of Precision Medicine and Drug Development, 2020, 5, 313-316.	0.7	4
65	Exploration of Reduced Doses and Short-Cycle Therapy for Darunavir/Cobicistat in Patients with HIV Using Population Pharmacokinetic Modeling and Simulations. Clinical Pharmacokinetics, 2021, 60, 177-189.	3.5	4
66	Population Pharmacokinetics of Temocillin Administered by Continuous Infusion in Patients with Septic Shock Associated with Intra-Abdominal Infection and Ascitic Fluid Effusion. Antibiotics, 2022, 11, 898.	3.7	4
67	Impact of CYP3A4*22 Allele on Sirolimus Dose Requirement in Kidney Transplant Patients. Transplantation, 2012, 94, 575.	1.0	2
68	HYGIEIA: HYpothesizing the Genesis of Infectious Diseases and Epidemics through an Integrated Systems Biology Approach. Viruses, 2022, 14, 1373.	3.3	2
69	Influence of Drug Exposure and Genetic Variation on Paclitaxelâ€"Induced Neurotoxicity. Annals of Oncology, 2012, 23, ix534.	1.2	1
70	Optimal sampling strategies for darunavir and external validation of the underlying population pharmacokinetic model. European Journal of Clinical Pharmacology, 2021, 77, 607-616.	1.9	1
71	Effect of four ABCB1 genetic polymorphisms on the accumulation of darunavir in HEK293 recombinant cell lines. Scientific Reports, 2021, 11, 9000.	3.3	1
72	Acute intoxication with nevirapine in an HIV-1-infected patient: clinical and pharmacokinetic follow up. Aids, 2009, 23, 1291-1293.	2.2	0

#	Article	IF	Citations
73	191 Morphine Premedication for Intubation in Preterm Infants - A Pharmacokinetic and Pharmacogenetic Report. Archives of Disease in Childhood, 2012, 97, A55-A55.	1.9	0
74	Cytochrome P450 genotype and aggressive behavior on selective serotonin reuptake inhibitors. Pharmacogenomics, 2018, 19, 1097-1099.	1.3	0